Two cases of systemic mastocytosis with RUNX1-RUNX1T1 positive acute myeloid leukemia treated with sequential avapritinib after allogeneic hematopoietic stem cell transplantation and literature review
10.3760/cma.j.cn121090-20240313-00092
- VernacularTitle:异基因造血干细胞移植后序贯阿伐替尼治疗系统性肥大细胞增多症伴RUNX1-RUNX1T1阳性急性髓系白血病2例并文献复习
- Author:
Juan WANG
1
;
Yingling ZU
;
Ruirui GUI
;
Zhen LI
;
Yanli ZHANG
;
Jian ZHOU
Author Information
1. 郑州大学附属肿瘤医院，河南省肿瘤医院血液科，郑州 450008
- From:
Chinese Journal of Hematology
2024;45(5):505-508
- CountryChina
- Language:Chinese
-
Abstract:
Systemic mastocytosis (SM) with RUNX1-RUNX1T1 positive acute myeloid leukemia (AML) is a rare myeloid tumor with no standard treatment. Two cases of SM patients with RUNX1-RUNX1T1 positive AML treated with sequential avapritinib after allogeneic hematopoietic stem cell transplantation (allo-HSCT) were reported in Henan Cancer Hospital. Mast cell in bone marrow disappeared, C-KIT mutation and RUNX1-RUNX1T1 fusion gene remained negative. Allo-HSCT sequential avapritinib is an effective treatment for SM patients with RUNX1-RUNX1T1 positive AML.
